Perrigo (NYSE:PRGO) Trading Down 4.4% – Should You Sell?

Perrigo Company plc (NYSE:PRGO) shares were down 4.4% on Wednesday . The stock traded as low as $12.29 and last traded at $12.2830. Approximately 110,652 shares were traded during trading, a decline of 97% from the average session volume of 3,182,696 shares. The stock had previously closed at $12.85.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PRGO. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Trading Up 1.0%

The firm has a 50 day moving average of $10.79 and a 200 day moving average of $11.45. The firm has a market cap of $1.78 billion, a PE ratio of -1.02, a P/E/G ratio of 1.45 and a beta of 0.51. The company has a quick ratio of 1.32, a current ratio of 2.32 and a debt-to-equity ratio of 1.31.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.11. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company’s revenue was down 3.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities analysts anticipate that Perrigo Company plc will post 2.2 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be given a dividend of $0.29 per share. The ex-dividend date is Friday, August 28th. This represents a $1.16 annualized dividend and a dividend yield of 9.0%. Perrigo’s dividend payout ratio (DPR) is -9.27%.

Institutional Trading of Perrigo

A number of hedge funds have recently bought and sold shares of the company. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Perrigo during the 2nd quarter valued at $4,066,000. Handelsbanken Fonder AB increased its position in shares of Perrigo by 20.7% in the second quarter. Handelsbanken Fonder AB now owns 50,200 shares of the company’s stock valued at $522,000 after acquiring an additional 8,600 shares during the period. GAMMA Investing LLC raised its stake in shares of Perrigo by 58.3% during the second quarter. GAMMA Investing LLC now owns 14,733 shares of the company’s stock valued at $153,000 after acquiring an additional 5,427 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Perrigo by 25.5% during the first quarter. Bank of America Corp DE now owns 1,568,598 shares of the company’s stock worth $16,847,000 after purchasing an additional 318,248 shares during the period. Finally, RBF Capital LLC bought a new stake in shares of Perrigo in the first quarter worth about $1,933,000. Institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.